The development and clinical integration of anti-HER2 therapies, including trastuzumab, pertuzumab, lapatinib, neratinib, and trastuzumab emtansine (T-DM1), has resulted in extended survival in patients with HER2-positive breast cancer [3–7]. The gene discussed is ERBB2; the disease is breast carcinoma.